Article PDF
Avoid common mistakes on your manuscript.
References
Breslow R. Artificial enzymes, cancer chemotherapy, conjugation and nanoelectronics, and prebiotic chemistry. Sci China Chem, 2011, 54: 1803–1814
Gan JH, Sheng J, Huang Z. Chemical and structural biology of nucleic acids and protein-nucleic acid complexes for novel drug discovery. Sci China Chem, 2011, 54: 3–23
Wang F, Chen Y, Huang Y, Jin HW, Zhang LR, Yang ZJ, Zhang LH. Synthesis, physicochemical and biological properties of oligonucleotides incorporated with amino-isonucleosides. Sci China Chem, 2012, 55: 70–79
Chen X, Hao ZY, Chen PR. Protein photocrosslinking reveals dimer of dimers formation on MarR protein in Escherichia coli. Sci China Chem, 2012, 55: 106–111
Chen MJ, Qu DZ, Chi WL, Wang W, Ren XS, Cong SJ, Liang PZ, Feng SP, Zhang BL. 5-Ethynyl-2′-deoxyuridine as a molecular probe of cell proliferation for high-content siRNA screening assay by “click” chemistry. Sci China Chem, 2011, 54: 1702–1710
Zhao DS, Chen YX, Liu Q, Zhao YF, Li YM. Exploring the binding mechanism of thioflavin-T to the β-amyloid peptide by blind docking method. Sci China Chem, 2012, 55: 112–117
Sun W, Li J, Li WH, Su LJ, Du LP, Li MY. Design of OFF/ON fluorescent thiol probes based on coumarin fluorophore. Sci China Chem, 2012, 55: 1776–1780
Xu JR, Wang H, Chen HZ. Muscarinic acetylcholine receptor modulators derived from natural toxins and diverse interaction modes. Sci China Chem, 2013, 56: 1333–1343
Wang Ting. The complexity of G-protein coupled receptor-ligand interactions. Sci China Chem, 2013, 56: 1344–1350
Shan C, Tan JH, Ou TM, Huang ZS. Natural products and their derivatives as G-quadruplex binding ligands. Sci China Chem, 2013, 56: 1351–1363
Xuan SY, Liang H, Wang Z, Yan AX. Classification of blocker and non-blocker of hERG potassium ion channel using a support vector machine. Sci China Chem, 2013, 56: 1413–1423
Zhang GD, Ge H, Gu Q, Xu J. Predicting hiCE inhibitors based upon pharmacophore models derived from the receptorand its ligands. Sci China Chem, 2013, 56: 1402–1412
Liao C, Yao RS. Diversity evolution and jump of Polo-like kinase 1 inhibitors. Sci China Chem, 2013, 56: 1392–1401
Tao WX, Zhu MH, Deng ZX, Sun YH. Biosynthesis of tetronate antibiotics: A growing family of natural products with broad biological activities. Sci China Chem, 2013, 56: 1364–1371
Zhang J, Zhu MY, Lin YN, Zhou HC. The synthesis of benzoxaboroles and their applications in medicinal chemistry. Sci China Chem, 2013, 56: 1372–1381
Cao ZF, Yang P, Zhou QS. Multiple biological functions and pharmacological effects of lycorine. Sci China Chem, 2013, 56: 1382–1391
Hao M, Cheng T, Wang Y, Bryant HS. Web search and data mining of natural products and their bioactivities in PubChem. Sci China Chem, 2013, 56: 1424–1435
Author information
Authors and Affiliations
Additional information
XU Jun received his Ph.D. degree from University of Science & Technology of China in 1989 and conducted his postdoctoral research work at Australian National University (ANU) and McGill University in 1990–1993. He worked in the US pharmaceutical industry for over 20 years, held the senior positions, such as, R&D Director, Research Fellow, etc. for Bio-Rad Sadtler Labs, DPI/Biofocus, Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI), OMG (now Accelrys) and Tripos. He became a Professor in Medicinal Chemistry & CADD and founding Director of Research Center for Drug Discovery (RCDD) at Sun Yat-sen University since 2009. His recent research interests include anti-virus or metabolic syndrome drug discovery, and high performance computing algorithm applied in biomedical innovations.
HAGLER T. Arnold was a theoretical/computational chemist in the labs of Harold Scheraga at Cornell and then Shneior Lifson at the Weitzman Institute. Following his postdoc with Shneior he joined the faculty of the Weitzman. In 1984, Dr. Hagler founded Biosym, and served as CEO. His company introduced a variety of software tools for structure based drug design. From 2000 to 2003, he served as President of Structural Proteomics and VP of Discovery Partners, a CRO of which it was a subsidiary. Dr. Hagler is currently VP of computational structural biology at Shifa and adjunct professor in the departments of Chemistry and Biochemistry and Molecular Biology at University of Massachusetts, Amherst (UMass Amherst) and adjunct professor of Pharmaceutical Chemistry at University of California, San Francisco (UCSF). He is focusing on the design of ligands to target the androgen receptor, a prostate cancer target.
Rights and permissions
About this article
Cite this article
Xu, J., Hagler, A.T. Preface. Sci. China Chem. 56, 1331–1332 (2013). https://doi.org/10.1007/s11426-013-4982-x
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11426-013-4982-x